Banco Santander S.A. Has $6.87 Million Holdings in PerkinElmer, Inc. (NYSE:PKI)

Banco Santander S.A. boosted its holdings in shares of PerkinElmer, Inc. (NYSE:PKIGet Rating) by 13.1% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 39,402 shares of the medical research company’s stock after buying an additional 4,570 shares during the quarter. Banco Santander S.A.’s holdings in PerkinElmer were worth $6,874,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. UMB Bank N A MO acquired a new position in PerkinElmer during the fourth quarter worth approximately $29,000. Allworth Financial LP grew its position in shares of PerkinElmer by 14,100.0% in the first quarter. Allworth Financial LP now owns 284 shares of the medical research company’s stock valued at $50,000 after purchasing an additional 282 shares during the last quarter. Covestor Ltd acquired a new position in shares of PerkinElmer in the fourth quarter valued at approximately $58,000. Quadrant Capital Group LLC grew its position in shares of PerkinElmer by 33.9% in the fourth quarter. Quadrant Capital Group LLC now owns 395 shares of the medical research company’s stock valued at $79,000 after purchasing an additional 100 shares during the last quarter. Finally, GraniteShares Advisors LLC acquired a new position in shares of PerkinElmer in the fourth quarter valued at approximately $119,000. Institutional investors and hedge funds own 89.27% of the company’s stock.

Insider Buying and Selling

In related news, insider James M. Mock sold 5,025 shares of PerkinElmer stock in a transaction that occurred on Friday, June 24th. The shares were sold at an average price of $145.49, for a total value of $731,087.25. Following the sale, the insider now owns 27,577 shares of the company’s stock, valued at approximately $4,012,177.73. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, insider James M. Mock sold 5,025 shares of the business’s stock in a transaction on Friday, June 24th. The shares were sold at an average price of $145.49, for a total transaction of $731,087.25. Following the completion of the transaction, the insider now directly owns 27,577 shares in the company, valued at approximately $4,012,177.73. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Andrew Okun sold 3,173 shares of the business’s stock in a transaction on Monday, August 1st. The shares were sold at an average price of $165.42, for a total transaction of $524,877.66. Following the transaction, the insider now owns 6,391 shares of the company’s stock, valued at $1,057,199.22. The disclosure for this sale can be found here. In the last quarter, insiders have sold 13,898 shares of company stock valued at $2,083,263. 0.52% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several research firms have recently commented on PKI. Barclays upped their target price on PerkinElmer from $125.00 to $149.00 and gave the company an “underweight” rating in a research report on Tuesday. Bank of America downgraded PerkinElmer from a “buy” rating to a “neutral” rating and set a $178.00 price target on the stock. in a research report on Tuesday. Robert W. Baird increased their price target on PerkinElmer from $198.00 to $202.00 and gave the stock an “outperform” rating in a research report on Tuesday. The Goldman Sachs Group reduced their price target on PerkinElmer from $200.00 to $175.00 and set a “neutral” rating on the stock in a research report on Thursday, July 14th. Finally, Citigroup reduced their price target on PerkinElmer from $185.00 to $170.00 in a research report on Wednesday, May 4th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, PerkinElmer currently has a consensus rating of “Hold” and a consensus price target of $161.13.

PerkinElmer Stock Performance

Shares of PKI opened at $153.72 on Friday. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.02 and a quick ratio of 1.43. The stock has a 50-day moving average of $144.81 and a 200-day moving average of $159.15. The company has a market cap of $19.39 billion, a PE ratio of 28.79, a P/E/G ratio of 0.42 and a beta of 1.12. PerkinElmer, Inc. has a one year low of $130.65 and a one year high of $203.16.

PerkinElmer (NYSE:PKIGet Rating) last issued its earnings results on Monday, August 1st. The medical research company reported $2.32 EPS for the quarter, beating the consensus estimate of $2.01 by $0.31. PerkinElmer had a return on equity of 16.68% and a net margin of 13.21%. The company had revenue of $1.23 billion during the quarter, compared to the consensus estimate of $1.20 billion. During the same period last year, the business posted $2.83 EPS. The firm’s revenue for the quarter was up .1% compared to the same quarter last year. On average, equities research analysts predict that PerkinElmer, Inc. will post 7.83 EPS for the current fiscal year.

PerkinElmer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, November 11th. Investors of record on Friday, October 21st will be issued a $0.07 dividend. The ex-dividend date of this dividend is Thursday, October 20th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.18%. PerkinElmer’s dividend payout ratio (DPR) is presently 5.24%.

About PerkinElmer

(Get Rating)

PerkinElmer, Inc provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services.

Featured Stories

Institutional Ownership by Quarter for PerkinElmer (NYSE:PKI)

Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.